PA
NMRA icon

Parallel Advisors’s Neumora Therapeutics NMRA Stock Holding History

Parallel Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$544 Hold
279
– – ﹤0.01% 3657
2025
Q4 		$499 Buy
+279
New +$611 ﹤0.01% 3407

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Parallel Advisors's NMRA Position: Q1 2026 in Review

Parallel Advisors held its Neumora Therapeutics (NMRA) position steady in Q1 2026 at 279 shares worth $544. The position accounts for ﹤0.01% of the portfolio, ranked #3657.

Parallel Advisors first reported a position in NMRA in Q4 2025 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Parallel Advisors held 279 shares of Neumora Therapeutics worth $544 as of Q1 2026.
  • Parallel Advisors left its Neumora Therapeutics share count unchanged in Q1 2026.
  • Neumora Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3657 holding.
  • Parallel Advisors first reported a position in Neumora Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.